A Peek Into The Market Before The Trading Starts
Pre-open movers US stock futures are mostly flat this morning, as investors are awaiting economic data. Futures for the Dow Jones Industrial Average dropped 3 points to 13,227.00 and S&P 500 index futures fell 1.70 points to 1,425.50. Nasdaq 100 futures declined 1.50 points to 2,668.75.
A Peek Into Global Markets European markets were lower today. The STOXX Europe 600 Index fell 0.29%, London's FTSE 100 Index dropped 0.25%, French CAC 40 Index declined 0.05% and German DAX 30 index fell 0.32%.
Asian markets ended mostly lower, with Japan's Nikkei Stock Average rising 1.68%, China's Shanghai Composite dropping 1.02% and Australia's S&P/ASX 200 rising 0.02%. Hong Kong's Hang Seng Index fell 0.26% and India's Sensex dropped 0.65%.
Broker Recommendation Analysts at Jefferies upgraded Vera Bradley (NASDAQ: VRA) from “hold” to “buy.” The target price for Vera Bradley has been raised from $22 to $35.
Vera Bradley shares gained 1.41% to $24.48 in pre-market trading.
- Pier 1 Imports (NYSE: PIR) reported a 3% rise in its fiscal third-quarter earnings and lifted its full-year earnings forecast. To read the full news, click here.
- International Game Technology (NYSE: IGT) today announced it has agreed to a deal to provide mobile games to Paddy Power in a significant extension to the companies' existing partnership. To read the full news, click here.
- Oncolytics Biotech (NASDAQ: ONCY) today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018). To read the full news, click here.
- ReachLocal (NASDAQ: RLOC) today announced that its Board of Directors has amended its previously announced share repurchase program to increase the total authorized repurchase amount by $6 million, to a total authorization of $26 million. To read the full news, click here.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.